DE60110897D1 - Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse - Google Patents

Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse

Info

Publication number
DE60110897D1
DE60110897D1 DE60110897T DE60110897T DE60110897D1 DE 60110897 D1 DE60110897 D1 DE 60110897D1 DE 60110897 T DE60110897 T DE 60110897T DE 60110897 T DE60110897 T DE 60110897T DE 60110897 D1 DE60110897 D1 DE 60110897D1
Authority
DE
Germany
Prior art keywords
waxest
cholesterylester
avasimibe
throat
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60110897T
Other languages
English (en)
Other versions
DE60110897T2 (de
Inventor
Reynold Homan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE60110897D1 publication Critical patent/DE60110897D1/de
Application granted granted Critical
Publication of DE60110897T2 publication Critical patent/DE60110897T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60110897T 2000-02-02 2001-01-23 Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse Expired - Fee Related DE60110897T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17977800P 2000-02-02 2000-02-02
US179778P 2000-02-02
PCT/US2001/002190 WO2001056556A2 (en) 2000-02-02 2001-01-23 Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders

Publications (2)

Publication Number Publication Date
DE60110897D1 true DE60110897D1 (de) 2005-06-23
DE60110897T2 DE60110897T2 (de) 2006-03-23

Family

ID=22657957

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60110897T Expired - Fee Related DE60110897T2 (de) 2000-02-02 2001-01-23 Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse

Country Status (34)

Country Link
US (2) US6730703B2 (de)
EP (1) EP1263421B1 (de)
JP (1) JP2003531113A (de)
KR (1) KR20020073574A (de)
CN (1) CN1398182A (de)
AP (1) AP2002002612A0 (de)
AT (1) ATE295724T1 (de)
AU (1) AU781563B2 (de)
BG (1) BG107042A (de)
BR (1) BR0107954A (de)
CA (1) CA2398219A1 (de)
CR (1) CR6712A (de)
DE (1) DE60110897T2 (de)
DZ (1) DZ3288A1 (de)
EA (1) EA004255B1 (de)
EE (1) EE200200429A (de)
ES (1) ES2239145T3 (de)
GE (1) GEP20043286B (de)
HR (1) HRP20020717A2 (de)
HU (1) HUP0301010A3 (de)
IL (1) IL150865A0 (de)
IS (1) IS6478A (de)
MA (1) MA26872A1 (de)
MX (1) MXPA02007309A (de)
NO (1) NO20023659L (de)
NZ (1) NZ520330A (de)
OA (1) OA12173A (de)
PL (1) PL357041A1 (de)
PT (1) PT1263421E (de)
SK (1) SK10972002A3 (de)
UA (1) UA75345C2 (de)
WO (1) WO2001056556A2 (de)
YU (1) YU57502A (de)
ZA (1) ZA200206075B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1281399A3 (de) * 2001-08-01 2004-02-11 Warner-Lambert Company Hemmer mit doppelter Wirkung auf Wachsester- und Cholesterylestersynthese zur Hemmung der Sebumproduktion
US20050031699A1 (en) 2003-06-26 2005-02-10 L'oreal Porous particles loaded with cosmetically or pharmaceutically active compounds
JP2007508291A (ja) 2003-10-09 2007-04-05 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 皮脂産生を減少させるためのマロンアミド誘導体を含んでなる医薬組成物
AU2006217529C1 (en) 2005-02-24 2013-03-07 Medicis Pharmaceutical Corporation Crystalline ACAT inhibitor
FR2903999B1 (fr) * 2006-07-19 2008-09-05 Galderma Res & Dev S N C Snc Modulateurs de sc4mol dans le traitement de l'acne ou de l'hyperseborrhee
FR2904002A1 (fr) * 2006-07-19 2008-01-25 Galderma Res & Dev S N C Snc Modulateurs de la lanosterol synthetase dans le traitement de l'acne ou de l'hyperseborrhee
FR2938342A1 (fr) * 2008-11-13 2010-05-14 Galderma Res & Dev Ciblage de modulateurs de ces1 et/ou ces3 dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010087964A2 (en) 2009-01-28 2010-08-05 Nanobio Corporation Compositions for treatment and prevention of acne, methods of making the compositions, and methods of use thereof
BR112020025208A2 (pt) * 2018-06-21 2021-03-09 Dermavant Sciences GmbH Formulações tópicas de inibidores de dgat1 e seus métodos de uso

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4545977A (en) * 1985-01-11 1985-10-08 G. D. Searle & Co. Compositions and methods for treating severe acne with isotretinoin
US4751026A (en) 1986-03-24 1988-06-14 Warner-Lambert Company Substituted anilides of oleic, linoleic, or linolenic acid as inhibitors of acyl-coa:cholesterol acyltransferase
US4722927A (en) 1986-04-28 1988-02-02 Warner-Lambert Company Pyrimidine amides of oleic or linoleic acid, composition containing them and their use as inhibitors of acyl-CoA cholesterol acyltransferase
JPS6323848A (ja) 1986-07-11 1988-02-01 ワ−ナ−−ランバ−ト・コンパニ− Ω−（置換フエニルオキシ）−アルカン酸のアリ−ル−およびアラルキルアミド
US4716175A (en) 1987-02-24 1987-12-29 Warner-Lambert Company Saturated fatty acid amides as inhibitors of acyl-CoA:cholesterol acyltransferase
IE61716B1 (en) 1987-06-02 1994-11-30 Warner Lambert Co Antihyperlipidemic and antiatherosclerotic urea compounds
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
ATE61574T1 (de) 1987-07-02 1991-03-15 Warner Lambert Co N-((2,6-disubstituierte)-phenyl>-harnstoff und - carbamat-inhibitoren der acyl-coenzym a:cholesterol-acyltransferase.
US4999373A (en) 1988-03-30 1991-03-12 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US4868210A (en) 1988-03-30 1989-09-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5030653A (en) 1988-03-30 1991-07-09 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US5116848A (en) 1988-03-30 1992-05-26 Warner-Lambert Company N-(((2,6-disubstituted)phenyl)-n-diarylalkyl)ureas as antihyperlipidemic and antiatherosclerotic agents
US4948806A (en) 1988-03-30 1990-08-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic compounds and compositions
US4923896A (en) 1989-02-09 1990-05-08 Warner-Lambert Company N-(substituted aryl)-N'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US5155127A (en) 1989-02-09 1992-10-13 Warner-Lambert Company N-(substituted aryl)-n'-(substituted alkoxy)-ureas and thioureas as antihypercholesterolemic and antiatherosclerotic agents
US4994465A (en) 1989-02-17 1991-02-19 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic trisubstituted urea compounds
AU632809B2 (en) 1989-05-25 1993-01-14 Takeda Chemical Industries Ltd. Benzocycloalkane benzopyran and benzothiopyran urea derivatives and production thereof
CA2022346A1 (en) 1989-08-04 1991-02-05 Mitsubishi Chemical Corporation 1-phenylalkyl-3-phenylurea derivatives
MX22406A (es) 1989-09-15 1994-01-31 Pfizer Nuevos derivados de n-aril y n-heteroarilamidas y urea como inhibidores de acil coenzima a: acil transferasa del colesterol (acat).
TW205037B (de) 1989-10-06 1993-05-01 Takeda Pharm Industry Co Ltd
JPH05310678A (ja) 1990-01-22 1993-11-22 Mitsubishi Kasei Corp １−フェニルアルキル−３−フェニル尿素誘導体
US5362878A (en) 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
ES2125325T3 (es) 1992-01-23 1999-03-01 Pfizer Derivados de 4-fenil-3-(heteroarilureido)-1,2-dihidro-2-oxoquinolina como agentes antihipercolesterolemicos y antiateroscleroticos.
WO1993024458A1 (en) 1992-05-28 1993-12-09 Pfizer Inc. New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat)
US5565472A (en) 1992-12-21 1996-10-15 Pfizer Inc. 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-oxo-quinoline derivatives as antihypercholesterolemic and antiatherosclerotic agents
US5491172A (en) * 1993-05-14 1996-02-13 Warner-Lambert Company N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
US5596001A (en) 1993-10-25 1997-01-21 Pfizer Inc. 4-aryl-3-(heteroarylureido)quinoline derivatves
US5494172A (en) * 1994-05-12 1996-02-27 Miller Compressing Company Magnetic pulley assembly
US6133326A (en) * 1994-08-31 2000-10-17 Pfizer Inc Compositions and methods for decreasing sebum production
CA2335559A1 (en) * 1998-06-25 1999-12-29 Tularik Inc. Arylsulfonanilide phosphates
EP1324995A2 (de) * 2000-09-27 2003-07-09 Merck & Co., Inc. Benzopyrancarbonsäure derivate für die behandlung von diabetes und fettstörungen

Also Published As

Publication number Publication date
PL357041A1 (en) 2004-07-12
ATE295724T1 (de) 2005-06-15
BG107042A (bg) 2003-04-30
IL150865A0 (en) 2003-02-12
US20030060507A1 (en) 2003-03-27
EA200200764A1 (ru) 2002-12-26
EP1263421A2 (de) 2002-12-11
WO2001056556A2 (en) 2001-08-09
NO20023659L (no) 2002-09-25
US6730703B2 (en) 2004-05-04
DE60110897T2 (de) 2006-03-23
DZ3288A1 (en) 2001-08-09
AP2002002612A0 (en) 2002-09-30
CA2398219A1 (en) 2001-08-09
CN1398182A (zh) 2003-02-19
KR20020073574A (ko) 2002-09-27
AU781563B2 (en) 2005-06-02
AU2971801A (en) 2001-08-14
IS6478A (is) 2002-07-19
MXPA02007309A (es) 2002-11-29
UA75345C2 (en) 2006-04-17
EA004255B1 (ru) 2004-02-26
PT1263421E (pt) 2005-08-31
MA26872A1 (fr) 2004-12-20
HUP0301010A2 (hu) 2003-08-28
EP1263421B1 (de) 2005-05-18
EE200200429A (et) 2003-12-15
US20040161393A1 (en) 2004-08-19
CR6712A (es) 2004-01-14
WO2001056556A3 (en) 2002-03-07
YU57502A (sh) 2006-01-16
NZ520330A (en) 2004-02-27
NO20023659D0 (no) 2002-08-01
HUP0301010A3 (en) 2005-03-29
SK10972002A3 (sk) 2003-07-01
OA12173A (en) 2006-05-08
ES2239145T3 (es) 2005-09-16
BR0107954A (pt) 2002-10-22
ZA200206075B (en) 2003-10-30
HRP20020717A2 (en) 2003-12-31
GEP20043286B (en) 2004-07-26
JP2003531113A (ja) 2003-10-21

Similar Documents

Publication Publication Date Title
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE472325T1 (de) Intrakorporale medikamente zur photodynamischen behandlung von erkrankungen
ATE306481T1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
ATE293610T1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60223694D1 (de) Pflaster zur behandlung von funktionsstörungen und störungen des nagelwachstums
ATE323661T1 (de) Behandlung von mineralischen stoffen
ATE434444T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
DE69940131D1 (de) Mittel zur Behandlung von Erkrankungen der Speiseröhre
ATE384522T1 (de) Medikamente zur chemotherapeutischen behandlung von erkrankungen
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE60232251D1 (de) Pharmazeutische zusammensetzungen zur behandlung von asthma
DE69934877D1 (de) Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen
ATE293447T1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE338557T1 (de) Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE295174T1 (de) Arzneimittel zur behandlung von bluthochdruck
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
DE60110897D1 (de) Der duale inhibitor der cholesterylester und wachsester synthese avasimibe zur behandlung von erkrankungen des talgdrüse
ATE357912T1 (de) Intrakorporelle medikamente zur hoch- energetischen phototherapeutischen behandlung von krankheiten
DE60138733D1 (de) Arzneimittel zur behandlung und vermeidung neurogener schmerzen
DE60016047D1 (de) Dihydrobenzopyrane, dihydrobenzothiopyrane und tetrahydrochinoline zur behandlung cox-2-abhängiger krankheiten
DE60223810D1 (de) Organische nitrat-derivate zur behandlung von atherosklerose und vaskulären erkrankungen
ATE374197T1 (de) Indolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE314064T1 (de) L-acetylcarnitin und l-propionylcarnitin zusammensetzung zur verhütung und behandlung von nierenstörungen und nierenenkrankheit

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee